These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27870645)

  • 21. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK; Baeten JM
    Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV preexposure prophylaxis for adolescents and young adults.
    Allen E; Gordon A; Krakower D; Hsu K
    Curr Opin Pediatr; 2017 Aug; 29(4):399-406. PubMed ID: 28598901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
    Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
    Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-exposure prophylaxis (PrEP) in HIV-uninfected individuals with high-risk behaviour.
    Nadery S; Geerlings SE
    Neth J Med; 2013; 71(6):295-9. PubMed ID: 23956310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
    Nichols BE; Boucher CAB; van der Valk M; Rijnders BJA; van de Vijver DAMC
    Lancet Infect Dis; 2016 Dec; 16(12):1423-1429. PubMed ID: 27665989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults.
    Liegeon G
    Curr Opin HIV AIDS; 2022 Jul; 17(4):199-204. PubMed ID: 35762374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation.
    Landovitz RJ
    Top Antivir Med; 2015; 23(2):85-90. PubMed ID: 26200708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI; Okoromah CA
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007189. PubMed ID: 19160329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
    Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
    AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.
    van de Vijver DA; Nichols BE; Abbas UL; Boucher CA; Cambiano V; Eaton JW; Glaubius R; Lythgoe K; Mellors J; Phillips A; Sigaloff KC; Hallett TB
    AIDS; 2013 Nov; 27(18):2943-51. PubMed ID: 23939237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV preexposure prophylaxis in the real world.
    Daskalakis DC
    Top Antivir Med; 2014; 22(4):670-5. PubMed ID: 25398067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E; Cohan D
    AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group.
    Kowalska JD; Bursa D; Gökengin D; Jilich D; Tomazic J; Vasylyev M; Bukovinowa P; Mulabdic V; Antonyak S; Horban A;
    HIV Med; 2018 Oct; 19(9):629-633. PubMed ID: 29989332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Awareness and Acceptance of HIV Pre-exposure Prophylaxis among Medical Personnel and Men Who Have Sex with Men in Korea.
    Chang HH; Kim SW; Jung H; Lee SA; Park HK; Kim S; Lee JM; Choi JY
    J Korean Med Sci; 2018 Mar; 33(12):e91. PubMed ID: 29542300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
    Velloza J; Heffron R
    Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications of HIV PrEP trials results.
    Veronese F; Anton P; Fletcher CV; DeGruttola V; McGowan I; Becker S; Zwerski S; Burns D;
    AIDS Res Hum Retroviruses; 2011 Jan; 27(1):81-90. PubMed ID: 20969483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug Resistance During HIV Pre-Exposure Prophylaxis.
    Gibas KM; van den Berg P; Powell VE; Krakower DS
    Drugs; 2019 Apr; 79(6):609-619. PubMed ID: 30963509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.